General
Preferred name
NELFINAVIR MESYLATE
Synonyms
AG 1343 Mesylate ()
Viracept ()
AG1343 ()
Nelfin ()
Nelfinavir (AG 1343) Mesylate ()
Viracept, AG1343 ()
Nelfinavir mesilate ()
Nelfinavir methanesulfonate ()
AG-1343 ()
Nelfinaviri mesilas ()
Nelfinavir (Mesylate) ()
P&D ID
PD003077
CAS
159989-65-8
159989-64-7
Tags
natural product
drug
available
Drug Status
approved
Max Phase
Phase 4
Drug indication
Antiviral
First approval
1997
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Potent VEGFR, PDGFRbeta and KIT inhibitor
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
1
Compound Sets
9
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
NIH Clinical Collections (NCC)
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
24
Molecular Weight
663.3
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
5
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
2
cLogP
4.25
TPSA
156.27
Fraction CSP3
0.58
Chiral centers
5.0
Largest ring
6.0
QED
0.2
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Proteases/Proteasome
Target
HIV Protease
HIV protease inhibitor
COVID-19,HIV Protease
Primary Target
Other Proteases
MOA
Inhibitor
Source data
